Jazz PharmaceuticalsJAZZ
JAZZ
About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Employees: 2,800
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
168% more call options, than puts
Call options by funds: $66.4M | Put options by funds: $24.7M
89% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 53
43% more repeat investments, than reductions
Existing positions increased: 217 | Existing positions reduced: 152
8% more funds holding
Funds holding: 502 [Q4 2024] → 541 (+39) [Q1 2025]
1.01% more ownership
Funds ownership: 97.61% [Q4 2024] → 98.62% (+1.01%) [Q1 2025]
2% more capital invested
Capital invested by funds: $7.26B [Q4 2024] → $7.43B (+$171M) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 10 (+0) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$147
26%
upside
Avg. target
$168
44%
upside
High target
$202
73%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Jeffrey Hung | 42%upside $165 | Overweight Maintained | 22 Jul 2025 |
Needham Ami Fadia | 73%upside $202 | Buy Reiterated | 11 Jun 2025 |
Baird Joel Beatty | 33%upside $155 | Outperform Maintained | 7 May 2025 |
RBC Capital Gregory Renza | 48%upside $172 | Outperform Maintained | 7 May 2025 |
Piper Sandler David Amsellem | 26%upside $147 | Overweight Reiterated | 7 May 2025 |
Financial journalist opinion
Based on 6 articles about JAZZ published over the past 30 days
Negative
Zacks Investment Research
18 hours ago
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
PRNewsWire
1 week ago
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
DUBLIN , July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.
Neutral
PRNewsWire
2 weeks ago
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
– Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – DUBLIN , July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company's next leader.
Positive
Forbes
3 weeks ago
Is JAZZ Stock Undervalued At $110?
Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European Commission Marketing Authorization for Ziihera (zanidatamab) aimed at advanced HER2-Positive Biliary Tract Cancer. Ziihera is the first HER2-targeted therapy approved in the EU for this condition, with anticipated peak annual sales surpassing $2 billion.
Positive
Seeking Alpha
3 weeks ago
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
In recent months, Jazz Pharmaceuticals plc has remained a stock that has seen some decline in attention from retail investors. This comes amid the potential approval of Zepzelca in combination with Tecentriq as a therapy for first-line extensive-stage small cell lung cancer. Meanwhile, the crown jewel of Jazz Pharmaceuticals' oncology franchise is Ziihera, which is superior in efficacy to chemotherapy drugs and Enhertu in the treatment of biliary tract cancer and more.
Neutral
PRNewsWire
4 weeks ago
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial – DUBLIN , July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted conditional marketing authorization1 for Ziihera ® (zanidatamab), a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.2 BTCs, which include gallbladder cancer (GBC) and cholangiocarcinoma (CCA), are a rare and aggressive group of cancers,3 with most cases diagnosed at an advanced stage4 when curative surgery is no longer an option.5 , 6 , 7 Globally, approximately 26% of patients with BTC are HER2-positive,8 a biomarker associated with poorer outcomes compared to HER2-negative disease.9 Ziihera is the first HER2-targeted therapy given conditional authorization for HER2-positive BTC in the European Union (EU). Continued approval for this indication is contingent upon verification and description of clinical benefit in the ongoing Phase 3 HERIZON-BTC-302 trial, which is evaluating zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.10 "People with HER2-positive biliary tract cancer who progress after first-line therapy face a challenging prognosis, with limited treatment options, poor tolerability, and median overall survival of only six to nine months," said Arndt Vogel, MD, managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Germany.
Neutral
PRNewsWire
1 month ago
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m.
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate Novel intermediate analysis from the DUET trial cohort of patients taking >9 grams evaluated safety and changes in daytime sleepiness in adults with narcolepsy taking Xywav dosages of 9-12 grams per night For U.S. media and investors only DUBLIN , June 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced late-breaking Phase 4 data evaluating treatment benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in people with narcolepsy. These results are two of Jazz's four late-breaking abstracts presented today as oral presentations at SLEEP 2025.
Positive
Zacks Investment Research
1 month ago
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data For U.S. media and investors only DUBLIN , June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 IMforte study of Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and atezolizumab. The study met both primary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atezolizumab alone.
Charts implemented using Lightweight Charts™